ADAM10 is a drug target in AD, where an activation of the ADAM10 cleavage of APP is therapeutically desired in order to reduce generation of the neurotoxic Aβ peptide (Postina, 2012; Marcello et al, 2017). The gene discussed is APP; the disease is Alzheimer disease.